Influence of different adrenoceptor agonists and antagonists on physostigmine-induced yawning in rats. 1999

M R Zarrindast, and S Fazli-Tabai, and S Semnanian, and Y Fathollahi
Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Iran.

In the present study, effects of adrenoceptor agonists and antagonists on physostigmine-induced yawning was investigated. Intraperitoneal (i.p.) injection of different doses of physostigmine (0.03, 0.05, 0.1, and 0.2 mg/kg) induced yawning in rats. The maximum response was obtained by 0.2 mg/kg of the drug. The alpha1-adrenoceptor agonist, phenylephrine, and the alpha2-adrenoceptor agonist, clonidine, decreased yawning induced by physostigmine. Prazosin and higher doses of phenoxybenzamine reduced the inhibitory effect of phenylephrine. Higher doses of yohimbine also reduced the clonidine response. The adrenoceptor antagonists, prazosin, phenoxybenzamine, and propranolol, did not significantly alter the physostigmine response. However, yohimbine, or lower doses of prazosin, decreased the physostigmine response. It may be concluded that alpha1- and alpha2-adrenoceptor stimulation decreases the physostigmine-induced yawning behavior in rats.

UI MeSH Term Description Entries
D008297 Male Males
D010830 Physostigmine A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. Eserine
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D000322 Adrenergic Agonists Drugs that bind to and activate adrenergic receptors. Adrenomimetics,Adrenergic Agonist,Adrenergic Receptor Agonist,Adrenergic Receptor Agonists,Receptor Agonists, Adrenergic,Agonist, Adrenergic,Agonist, Adrenergic Receptor,Agonists, Adrenergic,Agonists, Adrenergic Receptor,Receptor Agonist, Adrenergic
D000704 Analysis of Variance A statistical technique that isolates and assesses the contributions of categorical independent variables to variation in the mean of a continuous dependent variable. ANOVA,Analysis, Variance,Variance Analysis,Analyses, Variance,Variance Analyses
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015000 Yawning An involuntary deep INHALATION with the MOUTH open, often accompanied by the act of stretching. Yawnings
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D018674 Adrenergic Antagonists Drugs that bind to but do not activate ADRENERGIC RECEPTORS. Adrenergic antagonists block the actions of the endogenous adrenergic transmitters EPINEPHRINE and NOREPINEPHRINE. Adrenergic-Blocking Agents,Adrenolytics,Antiadrenergic Agents,Adrenergic Antagonist,Adrenergic Blockaders,Adrenergic Blocker,Adrenergic Blockers,Adrenergic Receptor Antagonists,Adrenergic Receptor Blockaders,Adrenolytic Agents,Adrenolytic Drugs,Anti-Adrenergics,Antiadrenergics,Receptor Antagonists, Adrenergic,Adrenergic Blocking Agents,Agents, Adrenergic-Blocking,Agents, Adrenolytic,Agents, Antiadrenergic,Antagonist, Adrenergic,Antagonists, Adrenergic,Antagonists, Adrenergic Receptor,Anti Adrenergics,Blockaders, Adrenergic,Blockaders, Adrenergic Receptor,Blocker, Adrenergic,Blockers, Adrenergic,Drugs, Adrenolytic,Receptor Blockaders, Adrenergic

Related Publications

M R Zarrindast, and S Fazli-Tabai, and S Semnanian, and Y Fathollahi
March 1995, European journal of pharmacology,
M R Zarrindast, and S Fazli-Tabai, and S Semnanian, and Y Fathollahi
December 1995, Psychopharmacology,
M R Zarrindast, and S Fazli-Tabai, and S Semnanian, and Y Fathollahi
July 2003, Pharmacology & toxicology,
M R Zarrindast, and S Fazli-Tabai, and S Semnanian, and Y Fathollahi
July 2004, Behavioural pharmacology,
M R Zarrindast, and S Fazli-Tabai, and S Semnanian, and Y Fathollahi
August 1978, Life sciences,
M R Zarrindast, and S Fazli-Tabai, and S Semnanian, and Y Fathollahi
October 1997, Pharmacology & toxicology,
M R Zarrindast, and S Fazli-Tabai, and S Semnanian, and Y Fathollahi
January 1992, Pharmacology,
M R Zarrindast, and S Fazli-Tabai, and S Semnanian, and Y Fathollahi
January 2007, Current topics in medicinal chemistry,
M R Zarrindast, and S Fazli-Tabai, and S Semnanian, and Y Fathollahi
December 1989, Pharmacology, biochemistry, and behavior,
M R Zarrindast, and S Fazli-Tabai, and S Semnanian, and Y Fathollahi
January 2000, Polish journal of pharmacology,
Copied contents to your clipboard!